Biodexa Pharmaceuticals Plc
BDRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBiodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder. With a market capitalization of $933K, it sits in micro-cap territory. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Market Cap
$933,053
Beta
1.28
P/E (TTM)
0.00
P/E (Fwd)
—
EPS (TTM)
$520.84
EPS (Fwd)
$0.00
ROE
-42.0%
ROA
-40.1%
Cash
$3.2M
Total Debt
$0
Free CF
-$4.1M
52W Change
-98.8%
Annual Financials
Cash vs Debt
Where BDRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BDRX finished 83.04% below its 150-day moving average ($2.30) and 89.40% below its 200-day moving average ($3.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BDRX overbought or oversold?
At the October 20, 2026 close, BDRX's RSI(14) was 28.7, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Biodexa Pharmaceuticals Plc reports $3.2M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$4.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -42.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $699K (2022) to $0 (2025), a 100% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BDRX.